TBC Janssen-Cilag Pty Ltd
Product name
TBC
Sponsor
Accepted date
Oct-2023
Active ingredients
daratumumab
Proposed indication
For the treatment of patients with multiple myeloma.
Application type
C (new indication)
Publication date
Oct-2023